The rise of Viagra and its effect on the medicinal landscape presents a complicated question for shareholders. While the early sales figures were remarkable, the patent has lapsed, leading to a wave of generic alternatives that are chipping away at profit. Furthermore, the industry is facing challenges related to aging trends and evolving health… Read More